Michael J. Keating, M.B., B.S.
Department of Leukemia, Division of Cancer Medicine
About Dr. Keating
Over the last 30 years, he has been involved in clinical research in chronic lymphocytic leukemia (CLL). During this time the complete remission rate has risen dramatically from approximately 5% to 50 – 60%. This is associated with improvements in developmental therapeutic programs but also a dramatic improvement in the understanding of the biology and prognostic factors of CLL. CLL is a disease of the elderly and the characterization of other cancers in survivors of CLL is vitally important. Understanding of this comparison between incidence and characteristics of other cancers in CLL survivors is vitally important in its own right but must be integrated into clinical understanding of the disease. He is totally committed to providing clinical and intellectual resources at his disposal to support the program.
In the News
Present Title & Affiliation
Primary Appointment
Clinical Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1966 | University of Melbourne, Melbourne, AUS, MBBS, Medicine |
| 1966 | St. Vincent's Hospital, Clinical School, Fitzroy, AUS, MBBS, Medicine |
Postgraduate Training
| 1974-1975 | Fellow, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, TX |
| 1971-1973 | Third Assistant, St. Vincent's Hospital, University of Melbourne, Melbourne |
| 1970-1971 | Senior Registrar, St. Vincent's Hospital, University of Melbourne, Melbourne |
| 1970-1970 | Fellow, Royal Australasian College of Physicians, Sydney |
| 1969-1970 | Medical Registrar, St. Vincent's Hospital, Melbourne |
| 1967-1968 | Residency in Medicine Surgery, St. Vincent's Hospital, Fitzroy |
Experience & Service
Academic Appointments
Professor of Medicine and Internist, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2014
Selected Publications
Peer-Reviewed Articles
- Liu P, Wang K, Li J, Ogasawara MA, Xia Z, Wierda WG, Keating MJ, Li Y, Huang P. Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations. Haematologica 109(2):479-492, 2024. e-Pub 2024. PMID: 37646669.
- Corvigno S, Badal S, Spradlin ML, Keating M, Pereira I, Stur E, Bayraktar E, Foster KI, Bateman NW, Barakat W, Darcy KM, Conrads TP, Maxwell GL, Lorenzi PL, Lutgendorf SK, Wen Y, Zhao L, Thaker PH, Goodheart MJ, Liu J, Fleming N, Lee S, Eberlin LS, Sood AK. In situ profiling reveals metabolic alterations in the tumor microenvironment of ovarian cancer after chemotherapy. NPJ Precis Oncol 7(1):115, 2023. e-Pub 2023. PMID: 37923835.
- Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W. A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. Blood Adv 7(10):1958-1966, 2023. PMID: 36287248.
- Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O'Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia 32(11):2388-2398, 2018. e-Pub 2018. PMID: 29769624.
- Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget 8(13):22104-22112, 2017. e-Pub 2016. PMID: 27655665.
- Thompson PA, Tam CS, O'Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ. Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127(3):303-9, 2016. e-Pub 2015. PMID: 26492934.
- Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 115(13):2824-2836, 2009. PMID: 19402170.
- Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood 113(18):4171-4178, 2009. e-Pub 2009. PMID: 19131547.
- Tsimberidou AM, Wen S, McLaughlin P, O'Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol 27(6):904-910, 2009. e-Pub 2008. PMID: 19114699.
- Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value Of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112(5):1923-1930, 2008. e-Pub 2008. PMID: 18577710.
- Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112(4):975-980, 2008. e-Pub 2008. PMID: 18411418.
- Keating MJ, Bach C, Yasothan U, Kirkpatrick P. Bendamustine. Nat Rev Drug Discov 7(6):473-474, 2008. PMID: 18511926.
- Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 109(11):4679-4685, 2007. PMID: 17299097.
- Borthakur G, O'Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide and rituximab - incidence and predictors. Br J Haematol 136(6):800-805, 2007.
- Ferrajoli A, Faderl S, Keating MJ. Monoclonal antibodies in chronic lymphocytic leukemia. Expert Rev Anticancer Ther 6(9):1231-1238, 2006. PMID: 17020457.
- O'Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma 7(2):125-130, 2006. PMID: 17026823.
- Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin's transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 107(6):1294-1302, 2006. PMID: 16902984.
- Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma 47(5):827-836, 2006. PMID: 16753866.
- Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol 23(26):6325-6332, 2005. PMID: 16155015.
- Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23(18):4079-4088, 2005. e-Pub 2005. PMID: 15767648.
- Faderl SJ, Keating MJ. Treatment of chronic lymphocytic leukemia. Curr Hematol Rep 4(1):31-38, 2005. PMID: 15610657.
- Wierda W, O'Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology 23(18):4070-4078, 2005. PMID: 15767647.
Abstracts
- Jain N, Thompson PA, Burger JA, Ferrajoli A, Borthakur G, Bose P, Estrov ZE, Kadia TM, Takahashi K, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian HM, O'Brien SM, Keating MJ, Wierda WG. Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations. Blood 132(Supp 1):695, 2018.
Patient Reviews
CV information above last modified August 08, 2024